BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Neuroscience Research

Executive Summary:
BIIE 0246 is a highly selective antagonist of the neuropeptide Y Y2 receptor (Y2R), a G-protein-coupled receptor critical to neural and metabolic regulation [product]. It exhibits an IC₅₀ of 3.3 nM and Ki values of 8–15 nM for PYY3-36 binding, ensuring precise Y2R targeting [source]. BIIE 0246 blocks Y2R-mediated presynaptic inhibition, modulates post-prandial satiety, and displays anxiolytic-like effects in validated animal models (Fan et al., 2024). The compound is a white solid, soluble at 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol, and is stable at 4°C for short-term storage [datasheet]. It is recommended solely for research, not diagnostic or therapeutic use.

Biological Rationale

The neuropeptide Y (NPY) system is a central regulator of feeding, anxiety, and autonomic outflow. Y2 receptors are G-protein-coupled receptors (GPCRs) abundantly expressed in the central and peripheral nervous systems. They act primarily as presynaptic inhibitory autoreceptors, modulating neurotransmitter release and synaptic plasticity (Fan et al., 2024). Dysregulation of the NPY-Y2R axis is implicated in metabolic syndromes, anxiety disorders, and cardiovascular pathologies. Recent studies highlight the adipose-neural axis, where adipocyte-derived leptin activates sympathetic neurons to release NPY and drive pathological signaling via NPY receptors, including Y2R (Fan et al., 2024). BIIE 0246 enables researchers to specifically inhibit Y2R signaling, dissecting its role in these interconnected neural, metabolic, and cardiovascular processes. For a broader mechanistic overview, see BIIE 0246: Selective Y2 Receptor Antagonist for Neuroscience, which this article extends by focusing on translational and workflow integration.

Mechanism of Action of BIIE 0246

BIIE 0246 binds with high affinity to the Y2R orthosteric site, competitively inhibiting endogenous ligands such as NPY and PYY3-36. The compound's IC₅₀ is 3.3 nM, and Ki values range from 8–15 nM under standard receptor-binding assay conditions (25°C, Tris buffer, pH 7.4) [datasheet]. In hippocampal slice preparations, BIIE 0246 blocks NPY-induced presynaptic inhibition, restoring population excitatory postsynaptic potentials (EPSPs) [mechanistic report]. In peripheral tissues, such as the rat colon, BIIE 0246 fully inhibits PYY3-36-induced contractions, confirming functional antagonism [datasheet]. Its selectivity profile minimizes off-target effects on other NPY receptor subtypes, ensuring mechanistic clarity. This article clarifies the advanced mechanistic applications highlighted in BIIE 0246: Pioneering Y2 Receptor Antagonism for Neural Circuits by detailing quantitative benchmarks.

Evidence & Benchmarks

• BIIE 0246 exhibits high Y2R binding affinity (IC₅₀ = 3.3 nM; Ki = 8–15 nM) in radioligand displacement assays at 25°C, pH 7.4 (ApexBio BIIE 0246 datasheet: https://www.apexbt.com/biie-0246.html).
• Blocks NPY-induced inhibition of afterdischarge activity and EPSPs in rat hippocampal slices (in vitro, 32°C, ACSF buffer, pH 7.4) (https://melanocyte-stimulating-hormone-release-inhibiting-factor.com/...).
• Completely inhibits PYY3-36-induced contractions in rat colon smooth muscle assays (organ bath, 37°C, Krebs buffer) (https://www.apexbt.com/biie-0246.html).
• Attenuates PYY3-36-induced reduction in feeding in rodents, supporting a role in post-prandial satiety regulation (https://doi.org/10.1016/j.xcrm.2024.101559).
• Reduces anxiety-like behavior in the elevated plus-maze test (dose: 0.3–3 mg/kg, i.p., male Wistar rats) (https://peptide-yy.com/index.php?g=Wap&m=Article&a=detail&id=15902).

Applications, Limits & Misconceptions

BIIE 0246 is used to dissect Y2R-dependent signaling in neural, metabolic, and cardiovascular models. It enables precise analysis of presynaptic inhibition, feeding behavior, anxiety, and adipose-neural crosstalk. The compound is not suitable for clinical or diagnostic use and is intended exclusively for research. For comparative application details, see BIIE 0246: A Selective Y2 Antagonist Empowering Neuroscience, which this article updates with new experimental benchmarks.

Common Pitfalls or Misconceptions

• Not a pan-NPY receptor antagonist: BIIE 0246 is selective for Y2R and does not significantly inhibit Y1R, Y4R, or Y5R at standard concentrations (datasheet).
• Not indicated for human or veterinary therapy: The compound is for laboratory research only; efficacy and safety in humans are unestablished.
• Solution stability is limited: Long-term storage of solutions is not recommended due to potential degradation (datasheet).
• Y2R-independent effects possible at supraphysiological doses: Off-target actions may occur at concentrations above 10 μM.
• No direct effect on leptin or Y1R-mediated pathways: While Y2R inhibition impacts the NPY axis, BIIE 0246 does not block leptin or Y1R-driven effects directly (Fan et al., 2024).

Workflow Integration & Parameters

BIIE 0246 is supplied as a white solid with a molecular weight of 896.06 Da and formula C₄₉H₅₇N₁₁O₆. For in vitro studies, dissolve in DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml). Aliquot and store at 4°C; avoid repeated freeze-thaw cycles. Standard working concentrations range from 1–100 nM for cell-based assays and 0.3–3 mg/kg for rodent injections. Do not store solutions long-term. For detailed protocols, consult the BIIE 0246 product page.

Conclusion & Outlook

BIIE 0246 is a gold-standard reagent for probing Y2R-dependent mechanisms in neuroscience and metabolic research. Its high selectivity, reproducible efficacy, and well-characterized action profile make it indispensable for dissecting NPY signaling and the adipose-neural axis. Future studies may extend its use to advanced translational models of metabolism, satiety, and stress, within the boundaries established by current evidence (Fan et al., 2024).